Studies on monoclonal anti-idiotypic antibodies to human B cell leukemia

Studies on monoclonal anti-isotypic and anti-idiotypic antibodies against leukemia and myeloma: VI. Purification and relative affinity of monoclonal antibodies

In this study, the anti-idiotypic and anti-isotypic antibodies (McAbs) against IgM of the Patient with B chronic lymphocytic leukemia (B-CLL) were purified from hybridoma ascites by n-Octoic acid precipitation method. The purified McAbs have high purify and high antibody activity as evidenced by immunoelectrophoresis, SDS-PAGE and ELISA. Relative affinity of 11 McAbs was measured by using indirect ELISA and double antibody sandwich ELISA method. It was found that relative affinity of various McAbs to the same antigen was different. 11 McAbs could be divided into two groups by analysing their 50% maximum binding. The relative affinity of 4 McAbs in the culture supernatants was consistent with that of McAbs in the purified ascites. Our experimental results provide an important basis for rational application of these McAbs.

Studies on monoclonal anti-isotypic and anti-idiotypic antibodies against leukemia and myeloma: V. The effects of monoclonal antibodies and interferon on the levels of cyclic nucleotides in leukemic cell lines

After the leukemic cell lines were treated with monoclonal antibodies (McAbs) and interferon (IFN-alpha), the changes of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels in the corresponding leukemic cell lines were measured by radioimmunoassay. The results showed that when the ratio of antigen to antibody was 80 to 1, the cAMP levels in the leukemic cell lines were obviously higher than those in the controls while the cGMP levels were obviously lower after being treated with the corresponding McAbs for 16-24 h (P < 0.001). The average level of intracellular cAMP was remarkably increased and that of cGMP underwent no significant changes in the leukemic cell lines after treatment with IFN-alpha.

Studies on monoclonal anti-isotypic and anti-idiotypic antibodies against leukemia and myeloma: IV. Modulation of membrane fluidity of leukemic cell lines and tonsillar cell stimulated with McAbs

In this study the technique of labelling the cell membrane with DPH fluorescence polarization was used to observe the membrane fluidity of B lymphocytic cell lines and tonsillar cells from healthy persons; the modulation effect on membrane fluidity induced by McAbs against isotypic and idiotypic determinants of IgM from patients with leukemia was studied as well. The expression of the corresponding isotypic and idiotypic determinants of IgM on the cell membrane was determined. The results show that the membrane fluidity of leukemic cell lines is remarkably higher than that of tonsillar cells from healthy persons, and McAbs against isotypic determinants of leukemic IgM can enhance the membrane fluidity of all kinds of cells mentioned above. However, the anti-idiotypic monoclonal antibody increased only the membrane fluidity of leukemic cell lines. These results indicated that there was a close relationship between the effect of McAbs on cell membrane fluidity and the expression of corresponding isotypic and idiotypic determinants of IgM on the cell membrane.

Studies on monoclonal anti-idiotypic and anti-isotypic antibodies against leukemia and myeloma: III. Analysis of monoclonal antibodies recognizing the antigenic epitopes by use of ELISA additivity test and microcomputer grouping programme

ELISA double antibodies additivity test was employed to identify the epitopes which can be recognized by monoclonal antibodies (McAbs) against IgM of a patient with B chronic lymphocytic leukemia (B-CLL). The computer grouping programme analysis showed that 4 anti-isotype McAbs could be divided into two groups and 10 anti-idiotype McAbs could be divided into four groups. The result was consistent with that of the indirect ELISA, ELISA sandwich as well as ELISA inhibition test. The above findings suggested that there are at least 6 distinct IgM epitopes which can specifically react with 14 McAbs. Our study indicated that the combination of the ELISA additivity test and the computer grouping programme analysis provides a helpful tool for researchers into the relationship between the structure and function of antigens.

Studies on monoclonal anti-isotypic and anti-idiotypic antibodies against leukemia and myeloma: II. Preparation and characteristics of monoclonal anti-isotypic antibodies to IgM from B chronic lymphocytic leukemia

Five hybridomas producing McAbs against human serum IgM-isotype were obtained by fusing the myeloma NS-1 cell and the BALB/C murine spleen cell which had been immunized by serum IgM of patient with B chronic lymphocytic leukemia (B-CLL). These McAbs only reacted with human IgM, not with other immunoglobulins in ELISA and immune double diffusion test. An approximate positive rate of peripheral blood lymphocyte (PBL) was got when these McAbs and the McAbs against B cell were tested by indirect immunofluorescent assay. The positive rate was similar to that obtained by direct immunofluorescent test. Immunoblotting showed that the molecular weight of the antigen to these McAbs was 70-90 Kd, indicating that the antigen was IgM. The practical value of the McAbs against human IgM was also discussed.

Studies on monoclonal anti-isotypic and anti-idiotypic antibodies against leukemia and myeloma: I. Study on monoclonal anti-idiotypic antibodies against lambda chain protein of myeloma

We used lambda chain extracted from urine of patient with myeloma (IgD lambda) as antigen for immunizing BALB/C mice, and 86 hybridoma cell clones secreting monoclonal antibodies (McAb) were obtained after fusing twice and cloning 3-4 times. 15 of these clones secreted monoclonal anti-idiotypic antibodies (anti-Id McAb). The results showed that 12 of 15 anti-Id antibodies reacted only with homologous lambda chain and IgD, not with lambda chain, kappa chain, IgG, IgA, IgM, IgD, IgE, albumin and paraglobulin from normal subjects. Indirect immunofluorescent assay demonstrated that positive reaction rate between anti-Id McAbs and peripheral blood lymphocytes or bone marrow cells of the patient with myeloma was up to 23%. No reaction was observed between anti-Id McAb and peripheral blood lymphocytes or bone marrow cells from normal subjects. Some of these McAbs presented positive reaction with plasmacytoma cell lines cultured in our laboratory.